Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-12-16

FDA Approved: JYNARQUE — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

FDA approved a supplemental application for JYNARQUE (tolvaptan) from Otsuka America Pharmaceutical, potentially updating or expanding its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JYNARQUE (tolvaptan)

Snippet

SUPPL AP for JYNARQUE (TOLVAPTAN)